Omlin AG - Search Results

1

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G. Pezaro CJ, et al. Among authors: omlin ag. Eur Urol. 2014 Sep;66(3):459-65. doi: 10.1016/j.eururo.2013.11.044. Epub 2013 Dec 17. Eur Urol. 2014. PMID: 24411987

2

Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.

Koster KL, Zumstein V, Süveg K, Jochum W, Husarik DB, Omlin A. Koster KL, et al. BJU Int. 2023 Feb;131(2):173-176. doi: 10.1111/bju.15847. Epub 2022 Dec 5. BJU Int. 2023. PMID: 36468816 No abstract available.

3

Erratum: Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen.

Peres T, Omlin A. Peres T, et al. Aktuelle Urol. 2024 Apr;55(2):e1. doi: 10.1055/a-2335-3889. Epub 2024 Jun 6. Aktuelle Urol. 2024. PMID: 38843845 German. No abstract available.

4

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.

Fischer S, Götze TO, Omlin A, Baird RD, Dawson KM, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. Fischer S, et al. JCO Precis Oncol. 2022 Nov;6:e2200006. doi: 10.1200/PO.22.00006. JCO Precis Oncol. 2022. PMID: 36331248 Free PMC article. No abstract available.

5

The changing therapeutic landscape of castration-resistant prostate cancer.

Yap TA, Zivi A, Omlin A, de Bono JS. Yap TA, et al. Nat Rev Clin Oncol. 2011 Aug 9;8(10):597-610. doi: 10.1038/nrclinonc.2011.117. Nat Rev Clin Oncol. 2011. PMID: 21826082 Review.

6

[Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer].

Omlin A, Gillessen S. Omlin A, et al. Urologe A. 2012 Jan;51(1):8-14. doi: 10.1007/s00120-011-2737-x. Urologe A. 2012. PMID: 22258370 German.

7

Therapeutic options for advanced prostate cancer: 2011 update.

Omlin A, de Bono JS. Omlin A, et al. Curr Urol Rep. 2012 Apr;13(2):170-8. doi: 10.1007/s11934-012-0239-z. Curr Urol Rep. 2012. PMID: 22373838 Review.

8

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D, Olmos D, Ferraldeschi R, Maier G, Thompson E, Parker C, Attard G, de Bono J. Omlin A, et al. Eur Urol. 2013 Aug;64(2):300-6. doi: 10.1016/j.eururo.2012.12.029. Epub 2013 Jan 4. Eur Urol. 2013. PMID: 23313031

9

Development of therapeutic combinations targeting major cancer signaling pathways.

Yap TA, Omlin A, de Bono JS. Yap TA, et al. J Clin Oncol. 2013 Apr 20;31(12):1592-605. doi: 10.1200/JCO.2011.37.6418. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509311 Review.

10

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J. Sandhu SK, et al. Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22. Ann Oncol. 2013. PMID: 23524863 Free article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters